INmune therapy shows promise in Alzheimer’s, but cognitive test still to come

After reporting its TNF inhibitor reduced brain inflammation in Alzheimer’s disease patients, INmune will need to show that reducing inflammation translates into a cognitive benefit in a Phase II trial planned for next year. The study will be one of the first tests of the neuroinflammation theory

Read the full 473 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers